Conference Reports for NATAP

17th European AIDS Conference November 6-9 2019, Basel Back

Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates       EACS: Single Doses of Long-Acting Capsid Inhibitor GS-6207 Administered by Subcutaneous Injection Are Safe and Efficacious in People Living With HIV - (11/12/19)   EACS: GS-6207 Long Acting Capsid Inhibitor Safety & PK Subcutaneous - (11/12/19)   17th European AIDS Conference (EACS), 6-9 November 2019, Basel, Switzerland Reported by Jules Levin   Nicolas A Margot, Renee R Ram, Martin Rhee, Christian Callebaut Gilead Sciences Inc. Foster City, CA, USA